Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
CKD chronic kidney disease; BMI body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; eGFR estimated glomerular filtration rate; BUN blood urea nitrogen; Scr serum creatine; ALT glutamic-pyruvic transaminase; AST glutamic oxalacetic transaminase; 25(OH)D 25-hydroxyvitamin D; TG triglyceride; TC total cholesterol; LDL-C low-density lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol; NAGL neutrophil gelatinase-associated lipocalin; RBP retinol binding protein; RBC red blood cell; ADC apparent diffusion coefficient; ΔADC the cortico-medullary difference in apparent diffusion coefficient; M mesangial hypercellularity; E endothelial hypercellularity; S segmental sclerosis; T interstitial fibrosis/tubular atrophy; C crescent.
Source: Characteristics of the study population. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
This cross-sectional study recruited 127 patients (aged 18-65 years) who were diagnosed with IgAN by renal biopsy in a single center between April 2020 and April 2022.
Source: Methods.
The complete clinical and laboratory information at the time of renal biopsy of enrolled patients was collected, including age, gender, duration of kidney disease, body mass index, blood pressure, hypertension, urinary protein, estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), serum creatinine (Scr), hemoglobin, 25-hydroxyvitamin D [25(OH)D], liver function tests, fasting blood glucose, triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), serum neutrophil gelatinase-associated lipocalin (NGAL), retinol binding protein (RBP), urine titratable acid, urine ammonia, urinary RBC, 24-h urinary electrolytes, serum immunoglobulin A (IgA), serum immunoglobulin G (IgG), complement C3, complement C4, etc.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Delta corticomedullary apparent diffusion coefficient on MRI as a biomarker for prognosis in IgA nephropathy
Cross-sectional study · Renal Failure · 2024
Original publication title
Delta corticomedullary apparent diffusion coefficient on MRI as a biomarker for prognosis in IgA nephropathy
© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To explore the association of the cortico-medullary difference in apparent diffusion coefficient (ΔADC) with clinicopathological parameters of disease activity at the time of biopsy, and with the prognositic risk stratification in IgA nephropathy (IgAN) patients.
Source: ObjectivesAbstract: What methods does the paper describe?
We included 112 patients with biopsy-proven IgAN who measured ΔADC. Patients underwent a kidney biopsy and diffusion-weighted magnetic resonance imaging within one week of the biopsy. Clinicopathological characteristics were compared according to different ΔADC levels. The effect of ΔADC on eGFR and kidney fibrosis was explored using multivariate regression and ROC analysis. An individual’s 5-year risk probability of progressing to ESKD or decreasing of eGFR > 50% was calculated by the guidelines-recommended international risk-prediction tool in IgAN. The effect of ΔADC on prognostic risk stratification was assessed.
Net reclassification improvement (NRI) was used to evaluate the model performance.
Source: MethodsAbstract: Results
The average ΔADC was 168.89 ± 85.1 x10−6 mm2/s. ΔADC levels decreased significantly with increasing chronic kidney disease (CKD) stages (p = 0.0038). Spearman correlation analysis revealed that ΔADC was positively correlated with eGFR, hemoglobin, serum albumin, while negatively correlated with levels of serum creatine (Scr), blood urea nitrogen (BUN), T score of Oxford classification and Lee grades (p < 0.05). Moreover, we showed that ΔADC was independently associated with eGFR (β = 0.04, 95% CI = [0.003, 0.077], p = 0.033) demonstrated by a backward stepwise multivariate linear regression analysis.
Besides, ΔADC, a combination of ΔADC and eGFR showed an AUC of 0.776 (60% sensitivity and 85.3% specificity) and an AUC of 0.875 (100% sensitivity and 69.6% specificity) respectively for evaluating kidney interstitial fibrosis (IF) severity. Furthermore, ΔADC showed an AUC of 0.792 (95% CI 0.677-0.906) for differentiating higher progression risk categories from lower categories (specificity = 91.6%, sensitivity = 58.8%). The low-ΔADC group (≤ median value 167.1 × 10−6 mm2/s) was associated with 7.509-fold higher likelihood of higher progression risk compared to the high-ΔADC group (>167.1 × 10−6 mm2/s) in a fully-adjusted model.
And reclassification analyses confirmed that the final adjusted model improved NRI.
Source: ResultsAbstract: Conclusions
ΔADC was significantly associated with kidney function and enabled a reliable evaluation of kidney IF severity in IgAN patients. Low ΔADC can predict a high 5-year kidney progression risk in IgAN, independent of important clinical factors. Moreover, the predictive ability to identify patients at high risk of severe kidney fibrosis and adverse progression estimates with satisfactory accuracy, facilitating ΔADC a promising and noninvasive tool in complementarily evaluating disease activity and the prognostic risk stratification in patients with IgAN.
Source: ConclusionsAuthors’ abstract
Abstract
Objectives
To explore the association of the cortico-medullary difference in apparent diffusion coefficient (ΔADC) with clinicopathological parameters of disease activity at the time of biopsy, and with the prognositic risk stratification in IgA nephropathy (IgAN) patients.
Methods
We included 112 patients with biopsy-proven IgAN who measured ΔADC. Patients underwent a kidney biopsy and diffusion-weighted magnetic resonance imaging within one week of the biopsy. Clinicopathological characteristics were compared according to different ΔADC levels. The effect of ΔADC on eGFR and kidney fibrosis was explored using multivariate regression and ROC analysis. An individual’s 5-year risk probability of progressing to ESKD or decreasing of eGFR > 50% was calculated by the guidelines-recommended international risk-prediction tool in IgAN. The effect of ΔADC on prognostic risk stratification was assessed.
Net reclassification improvement (NRI) was used to evaluate the model performance.
Results
The average ΔADC was 168.89 ± 85.1 x10−6 mm2/s. ΔADC levels decreased significantly with increasing chronic kidney disease (CKD) stages (p = 0.0038). Spearman correlation analysis revealed that ΔADC was positively correlated with eGFR, hemoglobin, serum albumin, while negatively correlated with levels of serum creatine (Scr), blood urea nitrogen (BUN), T score of Oxford classification and Lee grades (p < 0.05). Moreover, we showed that ΔADC was independently associated with eGFR (β = 0.04, 95% CI = [0.003, 0.077], p = 0.033) demonstrated by a backward stepwise multivariate linear regression analysis.
Besides, ΔADC, a combination of ΔADC and eGFR showed an AUC of 0.776 (60% sensitivity and 85.3% specificity) and an AUC of 0.875 (100% sensitivity and 69.6% specificity) respectively for evaluating kidney interstitial fibrosis (IF) severity. Furthermore, ΔADC showed an AUC of 0.792 (95% CI 0.677-0.906) for differentiating higher progression risk categories from lower categories (specificity = 91.6%, sensitivity = 58.8%). The low-ΔADC group (≤ median value 167.1 × 10−6 mm2/s) was associated with 7.509-fold higher likelihood of higher progression risk compared to the high-ΔADC group (>167.1 × 10−6 mm2/s) in a fully-adjusted model.
And reclassification analyses confirmed that the final adjusted model improved NRI.
Conclusions
ΔADC was significantly associated with kidney function and enabled a reliable evaluation of kidney IF severity in IgAN patients. Low ΔADC can predict a high 5-year kidney progression risk in IgAN, independent of important clinical factors. Moreover, the predictive ability to identify patients at high risk of severe kidney fibrosis and adverse progression estimates with satisfactory accuracy, facilitating ΔADC a promising and noninvasive tool in complementarily evaluating disease activity and the prognostic risk stratification in patients with IgAN.
Publication and source details
Original title: Delta corticomedullary apparent diffusion coefficient on MRI as a biomarker for prognosis in IgA nephropathy
Zitao Wang; Ling Jiang; Fang Lu; Li Qian; Ying Pan; Chengning Zhang; Zhimin Huang; Ming Zeng; Bin Sun; Bo Zhang; Huijuan Mao; Yudong Zhang; Suyan Duan; Changying Xing; Yanggang Yuan
Renal Failure · 2024
Co-first authors of this study
Senior authors with equal contribution to this study
Supplemental data for this article can be accessed online at https://doi.org/10.1080/0886022X.2024.2441394.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T07:55:47.755136+00:00
DOI: 10.1080/0886022x.2024.2441394 · PMC11654037